Development of regenerative therapy for peri-implantitis using diabetic model
Project/Area Number |
17K11760
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Prosthodontics/ Dental materials science and
|
Research Institution | Kagoshima University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
西村 正宏 鹿児島大学, 医歯学域歯学系, 教授 (00294570)
石井 正和 鹿児島大学, 医歯学域歯学系, 助教 (00456683)
益崎 与泰 鹿児島大学, 医歯学域鹿児島大学病院, 助教 (80588103)
|
Project Period (FY) |
2017-04-01 – 2020-03-31
|
Project Status |
Completed (Fiscal Year 2019)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | インプラント / 糖尿病 / 歯学 |
Outline of Final Research Achievements |
Poorly controlled diabetes is hyperglycemic, resulting in infection risk and delayed healing. Therefore, it is a relative risk in implant treatment. In this study, ipligraphrosin, a drug for treating SGLT2 diabetes, was administered to GK rats, which are diabetic model rats, After implant insersion, we conducted histological evaluation, mechanical evaluation, serum biochemical evaluation, etc. We evaluated whether it would affect bone formation around the implant. As a result, compared with the non-administered group, ipriografrosin improved bone formation, mechanical strength, and showed no change in serum biochemistry.
|
Academic Significance and Societal Importance of the Research Achievements |
現在糖尿病は慢性疾患であり、今後も患者数は増加すると思われる.そのため治療薬として様々なものが投与される可能性があるため,インプラント治療を行う場合にはコントロールが行われているか充分に配慮される事,新規の糖尿病治療薬によるインプラント治療の影響も含めて検討を行わなければならない。今回はSGLT-2系の薬剤を使用することにより検討を行い、治療薬による骨形成への影響は少ないことが考えられた.
|
Report
(4 results)
Research Products
(1 results)